SOUTH SAN FRANCISCO, Calif. (AP) _ Global Blood Therapeutics Inc. (GBT) on Wednesday reported a loss of $74.9 million in its first quarter.

The South San Francisco, California-based company said it had a loss of $1.21 per share.

The results did not meet Wall Street expectations. The average estimate of 14 analysts surveyed by Zacks Investment Research was for a loss of $1.02 per share.

The biopharmaceutical company posted revenue of $39 million in the period, which also did not meet Street forecasts. Eleven analysts surveyed by Zacks expected $42.9 million.

Global Blood shares have decreased 8% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $39.83, a fall of 50% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on GBT at https://www.zacks.com/ap/GBT